Lb Pharmaceuticals (LBRX) Change in Accured Expenses (2024 - 2026)

Lb Pharmaceuticals' Change in Accured Expenses history runs 3 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 219.7% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at -$390000.0 (changed N/A YoY), while the FY2025 annual figure was -$910000.0, down 118.14% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $3.5 million, up from $2.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.5 million in Q1 2026, with the low at -$2.9 million in Q4 2024.
• The 3-year median for Change in Accured Expenses is -$464500.0 (2025), against an average of -$97500.0.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses jumped 167.18% in 2025, then surged 219.7% in 2026.
• Lb Pharmaceuticals' Change in Accured Expenses stood at -$2.9 million in 2024, then soared by 167.18% to $2.0 million in 2025, then soared by 76.28% to $3.5 million in 2026.
• Business Quant data shows LBRX's Change in Accured Expenses at $3.5 million in Q1 2026, $2.0 million in Q4 2025, and -$2.9 million in Q1 2025.